sacituzumab govitecan
gilead sciences
['#gi', 'tropics-02', 'breast', 'trodelvy', 'gilead']
 2022 updates:
#immunomedics's #trodelvy acquired by #gilead, elicited a statistically significant but below par benefit in phase iii tropics-02 trial among hr+/her2 #breastcancer #patients. learn more #asco #asco2022 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry